Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.48 |
| ▸ | ITGAV | P06756 | 10/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368255 | 0.90 | ITGB3 (0.58) | ITGB3ITGAVITGA2BMEN1KMT2A | |
| SCHEMBL6367673 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVITGA2BMAPTSUCNR1 | |
| SCHEMBL6368635 | 0.80 | HTR2B (0.44) | ITGB3ITGAVITGA2BMAPTMEN1 | |
| SCHEMBL6368243 | 0.80 | ITGB3 (0.57) | ITGB3ITGAVITGA2BMEN1KMT2A | |
| SCHEMBL7343426 | 0.79 | SUCNR1 (0.53) | ITGB3ITGAVITGA2BSUCNR1 | |
| SCHEMBL6367029 | 0.79 | MEN1 (0.43) | ITGB3ITGAVITGA2BMAPTMEN1 | |
| SCHEMBL6777410 | 0.79 | SUCNR1 (0.54) | ITGB3ITGAVITGA2BSUCNR1 | |
| SCHEMBL13418141 | 0.77 | EEF2K (0.50) | ITGB3ITGAVITGA2BSUCNR1L3MBTL1 | |
| SCHEMBL8369244 | 0.76 | ITGB3 (0.61) | ITGB3ITGAVITGA2BMAPTMEN1 | |
| SCHEMBL7194759 | 0.76 | ITGB3 (0.52) | ITGB3ITGAVITGA2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677308-B1 | INTEGRIN ANTAGONISTS; ANTITUMOR, ANTIMETASTASIS, ANTICARCINOGENIC AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS; OSTEOPOROSIS | G. D. SEARLE & CO. | 2004-01-13 | — | — | US | claimed |
| EP-0889876-B1 | META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES | SEARLE & CO (US) | 2001-07-25 | — | — | EP | claimed |
| US-20050176821-A1 | Meta-substituted phenylene sulphonamide derivatives | G. D. SEARLE & CO. (US) | 2005-08-11 | — | — | US | disclosed |
| US-6677308-B1 | INTEGRIN ANTAGONISTS; ANTITUMOR, ANTIMETASTASIS, ANTICARCINOGENIC AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS; OSTEOPOROSIS | G. D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| EP-0889876-B1 | META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES | SEARLE & CO (US) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176821-A1 | Meta-substituted phenylene sulphonamide derivatives | ITGB3, ITGB1, ITGA5 | ITGB3 1/4885ITGAV 6/4885ITGA2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.